Patent Application
20220409668
The present invention relates to a genetically modified human stem cell, in which said human stem cell comprises an exogenous nucleic acid comprising a region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 (CYP2B6*) protein of SEQ ID No. 1 or a variant or fragment thereof and an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof, functionally bound to a promoter, said exogenous nucleic acid having been integrated into one of the genomic safe harbors of said human stem cell. The invention also relates to the use of said cell for the treatment of cancer, particularly the solid tumours, and in particular hepatocellular carcinomas.
Liver cancers represent over 841,080 new cases worldwide annually, of which 90% are hepatocellular carcinomas. Hepatocellular carcinoma is the third cause of cancer mortality worldwide. Chronic infection by the hepatitis C (VHC) and hepatitis B (VHB) viruses or also alcoholic cirrhosis are the main causes of hepatocellular carcinoma. Furthermore, for the last 10 years, the emergence of nonalcoholic steatohepatitis (NASH) associated with the increase in obesity, pre-diabetic and type-2 diabetes conditions, is an emerging cause of hepatocarcinoma. Treatment for hepatocellular carcinoma is essential in order to avoid a fatal outcome. In light of the increase in patients having non-alcoholic steatohepatitis, it is highly probable that the number of patients with hepatocellular carcinoma will increase in the years to come. The spontaneous survival of patients with hepatocellular carcinoma is no greater than 15 months. The BCLC (Barcelona Cancer Liver Centre) classification allows 5 types of clinical situation to be distinguished.
Stages 0 and A (early stage) (15% of patients) define patients with an early diagnosis of disease, in good general health and having a hepatocellular carcinoma of less than 3 cm. These patients are eligible for tumour resection surgery and liver transplantation, which are the only curative treatments. Survival at 5 years is 60%.
Stage B (intermediate) relates to patients whose general state of health is maintained but having one or more hepatocellular carcinoma(s) the size of which is greater than 3 cm, without invasion of the hepatic portal vein or metastases. These patients may benefit from hepatic chemoembolization with doxorubicin. Median survival for these patients is 20 months.
Stage C (advanced) defines a patient having a hepatocarcinoma with portal invasion, ganglion and pulmonary metastases associated with a moderate change in their general state of health.
The treatment of reference at this advanced stage is Sorafenib, an antiangiogenic multikinase inhibitor administered via oral route, marketed under the name Nexavar® from Onyx/Bayer. In these patients, the median survival is 11 months. Other, second-line treatments have recently been approved. These are Regorafenib (kinase inhibitor) marketed under the name Stivarga® from Bayer and Nivolumab (anti-PD1 antibody) marketed under the name Opdivo®, from BMS. All these treatments have limited efficacy and are responsible for major adverse reactions (diarrhoea, weight loss, hand-foot syndrome and hypophosphataemia, arterial hypertension) often the cause of poor treatment adherence leading to suboptimal results.
Stage D relates to patients who have reached the palliative stage for which only supportive care can be offered.
Thus, a need therefore exists for new efficacious forms of cancer treatment, particularly the solid tumours and in particular hepatocellular carcinomas, in particular treatments capable of supplying controlled and sustained therapy, alone or in combination with other therapies, while improving the quality of life of the patient and reducing the adverse effects associated with the treatment.
In order to prevent and/or treat cancer and/or associated metastases, in particular the solid tumours, and particularly hepatocellular carcinoma and/or associated metastases, the inventors have developed a new genetically modified human stem cell capable of metabolizing cyclophosphamide and inducing immunological death of the tumour cells by eliciting a strong antitumor immune response.
Thus, the present invention relates to a genetically modified human stem cell, in which said human stem cell comprises an exogenous nucleic acid comprising a region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 (CYP2B6*) protein of SEQ ID No. 1 or a variant or fragment thereof, an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof, functionally bound to a promoter, said exogenous nucleic acid having been integrated into one of the genomic safe harbors of said human stem cell and characterized in that said genetically modified human stem cell is not an embryonic human stem cell.
Advantageously, the human stem cell is chosen from mesenchymal stem cells (hMSC), induced pluripotent stem cells (iPSC) and induced mesenchymal stem cells (iMSC).
Advantageously, the promoter used is a constitutive promoter, preferably the EF1-α promoter. Advantageously, the exogenous nucleic acid further comprises a selectable marker gene.
The present invention also relates to a method for obtaining the genetically modified human stem cell; said human stem cell was obtained by retroviral transduction with a viral vector comprising exogenous nucleic acid.
The present invention also relates to the genetically modified human stem cell for use thereof as a medicament and formulation thereof in a suitable form for administration thereof via transarterial route.
The present invention also relates to a method for selecting genetically modified stem cells comprising the steps of:
a) transducing the human stem cells with a viral vector comprising exogenous nucleic acid,
b) culturing the human stem cells in a predefined culture medium,
c) selecting the genetically modified human stem cells expressing the selectable marker gene on their membrane surface.
The present invention further relates to a pharmaceutical composition comprising the genetically modified human stem cell as active ingredient and at least one pharmaceutically acceptable excipient and optionally at least a second active ingredient, in particular an anti-cancer agent, said pharmaceutical composition being in a form suitable for administration thereof via transarterial route.
The invention also relates to a genetically modified human stem cell or pharmaceutical composition for use thereof in the prevention and/or the treatment of cancer and/or the cancer recurrences and/or associated metastases, preferably of the solid tumours, preferably the hepatocellular carcinomas and/or associated metastases.
Thus, the subject of the present invention is a genetically modified human stem cell, in which said human stem cell comprises an exogenous nucleic acid comprising a region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 (CYP2B6*) protein of SEQ ID No. 1 or a variant or fragment thereof, an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof, functionally bound to a promoter, said exogenous nucleic acid having been integrated into one of the safe harbor genes of said human stem cell and characterized in that said genetically modified human stem cell is not an embryonic human stem cell.
The inventors have shown, surprisingly, that the integration of exogenous nucleic acid into one of the genomic safe harbors is of prime importance to enable the genetically modified human stem cell to metabolize cyclophosphamide (CPA) and thus induce immunological death of the tumour cells. In addition, this integration of exogenous nucleic acid into one of the genomic safe harbors allows the genetically modified human stem cell to maintain its morphology and its doubling time. Furthermore, the inventors have shown that a single copy of the exogenous nucleic acid is integrated into one of the genomic safe harbors. The inventors have also shown that the use of genetically modified human stem cells according to the invention allows the complete eradication of solid tumours as well as a protection against recurrences and metastases by vaccinating effect.
In a particular embodiment of the invention, the stem cell is chosen from the human mesenchymal stem cells (hMSC), the induced pluripotent stem cells (iPSC) and the induced mesenchymal stem cells (iMSC).
Within the meaning of the present invention, the term “mesenchymal stem cells” or “hMSC” or “human mesenchymal stem cells” denotes multipotent stem cells capable of differentiating particularly into osteoblasts, chondrocytes, myocytes and adipocytes. The mesenchymal stem cells are located in the mesenchyma, the part of the embryonic mesoderm constituted by loosely packed fusiform or stellate cells. As used here, the mesenchymal stem cells comprise, non-limitatively, CD34-negative stem cells. In an embodiment of the invention, the human mesenchymal stem cells are isolated from the adipose tissue and/or from bone marrow.
Within the meaning of the present invention, the term “induced pluripotent stem cells” or “iPSC” or “human induced pluripotent stem cells” denotes a type of pluripotent stem cell similar to an embryonic stem cell but which is created when somatic cells (for example adult somatic cells) are reprogrammed to enter a state similar to that of an embryonic stem cell while maintaining expression of the factors that are important for maintaining the “pluripotency” of the embryonic stem cells (also called CSE or PSC), i.e. the capability thereof to engage in different differentiation pathways. Such factors can include certain embryonic genes (such as OCT4, SOX2 and LF4 transgenes). As used here, the term “pluripotent” denotes a cell or a cell line capable of differentiating into any differentiated cell type, for example, a capacity to develop into the three germ layers of development of the organism, specifically the endoderm, the mesoderm and the ectoderm.
Within the meaning of the present invention, the term “induced mesenchymal stem cells” or “iMSC” or “human induced mesenchymal stem cells” denotes mesenchymal stem cells derived from induced pluripotent stem cells (iPSC).
In a particular embodiment of the invention, the human stem cell is a mesenchymal stem cell (hMSC). In another particular embodiment of the invention, the human stem cell is an induced pluripotent stem cell (iPSC). In another particular embodiment of the invention, the human stem cell is an induced mesenchymal stem cell (iMSC).
Within the meaning of the present invention, the term “exogenous nucleic acid” denotes a nucleic acid that is not naturally present in the human stem cell according to the invention. The exogenous nucleic acid can be a genomic DNA, cDNA, natural DNA or obtained totally or partially by chemical synthesis. According to an embodiment of the invention, the exogenous nucleic acid has a therapeutic benefit.
In a particularly advantageous embodiment, the exogenous nucleic acid comprises a region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 (CYP2B6*) protein of SEQ ID No. 1 or a variant or fragment thereof, an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof.
In a particularly advantageous embodiment of the invention, the human cytochrome P450 2B6 protein is a mutant human cytochrome P450 2B6 protein, also called CYP2B6*, of SEQ ID No. 1 or a variant or fragment thereof, in which said variant or said fragment comprises 114V, 199M and 477 W residues as represented in the amino acid sequence SEQ ID No. 1.
Advantageously, said variant or fragment preserves a biological activity of a protein having the amino acid sequence SEQ ID No. 1.
The amino acid sequence of the wild-type (CYP2B6 WT) human cytochrome P450 2B6 protein is represented by the sequence SEQ ID No.3.
Advantageously, the mutant human cytochrome P450 2B6 (CYP2B6*) protein has an affinity for CPA that is more than 8 times greater than that of the wild-type protein (CYP2B6 WT), while preserving the same Vmax, particularly owing to the substitutions 1114V, L199M and V477 W as shown in SEQ ID No. 1. As described below, the variants and fragments of the amino acid sequence SEQ ID No. 1 are encompassed within the scope of the invention. However, all the mutant human cytochrome P450 2B6 proteins, variants and fragments of the invention as described herein retain Val in the position corresponding to residue 114 of amino acid sequence SEQ ID No.1, Met in the position corresponding to residue 199 of amino acid sequence SEQ ID No.1 and Trp in the position corresponding to residue 477 of the amino acid sequence SEQ ID No.1.
The amino acid sequence of the wild-type NADPH-cytochrome P450 reductase protein (NADPH WT) is represented by the sequence SEQ ID No.2. The variants and fragments of the NADPH-cytochrome P450 reductase protein of amino acid sequence SEQ ID No. 2, described below, also fall within the scope of the invention.
The variants of the proteins can be natural variants, such as splicing variants, alleles and isoforms, or can be produced by recombinant means. Variations of the amino acid sequence can be introduced by substitution, deletion or insertion of one or more codons in the nucleic acid sequence coding for the protein, leading to a modification of the amino acid sequence of the protein. Optionally, the variation can be of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 amino acids or more with any other amino acid. In addition or alternatively, the variation can be introduced by addition or deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 amino acids or more within the protein. The substitutions of amino acids can be conservative or non conservative. Preferably, the substitutions are conservative substitutions, in which an amino acid is substituted for another amino acid having similar structural and/or functional and/or chemical properties. Examples of conservative substitutions are listed below:
Ala (A) Val; Leu; Ile
Arg (R) Lys; Gln; Asn
Asn (N) Gln; His; Lys
Asp (D) Glu
Cys (C) Ser
Gln (Q) Asn
Glu (E) Asp
Gly (G) Pro; Ala; ala
His (H) Asn; Gln; Lys; Arg;
Ile (I) Leu; Val; Met; Ala;
norleucine Leu
Leu (L) norleucine; Ile; Met; Ala; Phe
Lys (K) Arg; Gln; Asn
Met (M) Leu; Phe; Ile
Phe (F) Leu; Val; Ile; Ala; Tyr
Pro (P) Ala
Ser (S) Thr
Thr (T) Ser
Trp (W) Tyr; Phe;
Tyr (Y) Trp; Phe; Thr; Ser;
Val (V) Ile; Leu; Met; Phe; Ala; norleucine.
The protein variants can include proteins that have at least approximately 80% amino acid sequence identity with a polypeptide sequence described herein. Advantageously, a protein variant will have at least approximately 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% amino acid sequence identity with a complete amino acid sequence or a fragment of an amino acid sequence of SEQ ID No.1 and/or SEQ ID No.2.
The amino acid sequence identity is defined as the percentage of amino acid residues of the variant sequence that are identical to the amino acid residues of the sequence of reference, after alignment of the sequences and if necessary, the introduction of holes in order to reach the percentage of maximum sequence identity, not envisaging conservative substitutions within the context of the sequence identity. The sequence identity can be determined over the entire length of the variant sequence, over the entire length of the sequence of reference, or both. The methods of sequent alignment and determination of sequence identity are well known in the art, for example, by using publicly available software such as BioPerl, BLAST, BLAST-2, CS-BLAST, FASTA, ALIGN, ALIGN-2, LALIGN, Jaligner, Matcher or the Megalign software (DNASTAR).
The protein fragments and the protein variants described in the present application are also encompassed by the invention. Such fragments can be truncated at the N-terminal end or at the C-terminal end, or can be devoid of internal amino acid residues outside of the N-terminal and C-terminal ends, for example, with respect to a total-length protein. Certain fragments are devoid of amino acid residues that are not essential to enzyme activity. Advantageously, said fragments are at least approximately 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 150, 200, 250, 300, 350, 400, 450, 500 amino acids or more in length.
The preferred fragments of the proteins described herein comprise all or part of the active site. The preferred fragments of the mutant human cytochrome P450 2B6 (CYP2B6*) protein comprise or are constituted by amino acids 1 to 490 of the complete-length sequence SEQ ID No. 1. The preferred fragments of NADPH-cytochrome P450 reductase protein comprise or are constituted by fragments comprising or constituted by amino acids 60 to 680 of the amino acid sequence SEQ ID No. 2.
The variants and fragments of the invention preferably preserve a biological activity of the complete protein. The variants and fragments of the human cytochrome P450 2B6 protein advantageously have an oxidation activity of a substrate such as cyclophosphamide (CPA) or another substrate, in particular by catalysing 4-OH-CPA hydroxylation.
In a particularly advantageous embodiment, said variants and fragments have an affinity for cyclophosphamide (CPA) greater than that of the human cytochrome P450 2B6 protein of sequence SEQ ID No. 3, preferably at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 times that of the wild-type sequence.
In a particularly advantageous embodiment, said variants and fragments have an affinity for CPA that is identical, substantially identical or greater than that of the mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1. Methods making it possible to assay said activity and said affinity are well known to a person skilled in the art and are particularly described in Nguyen et al., Mol. Pharmacol., 2008, 73: 1,122-1,133.
The variants and the fragments of the NADPH-cytochrome P450 reductase protein preferably have an activity of reduction of cytochrome c, preferably NADPH-dependent.
In a preferred embodiment, said variants and fragments have an activity that is identical, substantially greater than or equal to that of the complete-length NADPH-cytochrome P450 reductase protein (SEQ ID No. 2). Methods for assaying said activity are well known to a person skilled in the art and are particularly described in Yasukochi et al; Arch. Biochem. Biophys, 1980, 202: 491-498.
A person skilled in the art will be able to determine the amino acid residues that can be inserted, substituted or deleted without detracting from the activity of the protein, using knowledge of the protein structure available in the art and the publicly available molecular modelling techniques (see for example Nguyen et al. Mol. Pharmacol. 2008, 73: 1,122-1,133). The authorized variation can be determined by systematically carrying out amino acid insertions, deletions or substitutions in the sequence and testing the resulting variants for the activity demonstrated with respect to the wild protein.
Within the meaning of the present invention, the term “fusion protein” denotes a chimeric protein created by joining two or more genes coding for distinct proteins or protein fragments, such as different proteinaceous domains, in a single reading frame coding for a single translated protein.
The fusion protein of the present invention preferably comprises:
In a particularly advantageous embodiment, said fusion protein of sequence SEQ ID No.4 comprises:
The mutant human cytochrome P450 2B6 (CYP2B6*) protein of SEQ ID No. 1 or a variant or fragment thereof can be upstream or downstream of the NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof. Preferably, the mutant human cytochrome P450 2B6 (CYP2B6*) protein of SEQ ID No. 1 or a variant or fragment thereof is upstream of the NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof.
When the context permits, the term “proteins of the invention” and “the proteins disclosed herein” must be understood as encompassing said fusion proteins.
The proteins or protein fragments constituting the fusion protein can be separated by a linking peptide sequence or a spacer. The linking peptide sequence, also called “linker”, or spacer, serves to separate the proteins or the protein fragments of which they are composed, and assist the folding and the efficacious activity of the individual components. The linker or spacer peptide sequence can comprise an enzyme cleavage site to allow the polypeptide components to be separated by enzyme digestion. The linker or spacer peptide sequence can be, for example, of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 amino acids or more. Preferably, the linker or spacer peptide sequence has a length less than 10, less than 9, less than 8, less than 7, less than 6 or less than 5 amino acids. Examples of linker or spacer peptide sequence to be used in the fusion proteins of the present invention comprise (Ser)n Thr, where “n” is an integer, preferably 1, 2, 3, 4, 5, 6, 7, 8 or 9. In a preferred embodiment, the value of “n” is 5. In another preferred embodiment, the value of “n” is 3.
Within the meaning of the present invention, the term “genomic safe harbor” or “safe harbor” denotes a region of the genome where it is possible to integrate genetic material without disturbing the function, transcription and regulation of the native coding sequences, as well as the genetic structure. A “safe harbor” allows sufficient expression of the exogenous nucleic acid without predisposing the human stem cell according to the invention to a malignant transformation or affecting the function thereof.
In a particular embodiment of the invention, the exogenous nucleic acid is integrated into one of the genomic safe harbors. Advantageously, the exogenous nucleic acid is integrated into one of the genomic safe harbors selected from: the AAVS1 site on chromosome 19, the CCRS site on chromosome 3, the hROSA26 site on chromosome 3, the 323 site on chromosome 1, the 325 site on chromosome 8, the 289 site on chromosome 1, the 227 site on chromosome 1, the 229 site on chromosome 2, the 253 site on chromosome 2, the 255 site on chromosome 5, the 257 site on chromosome 7, the 259 site on chromosome 14, the 261 site on chromosome 17, the 263 site on chromosome X, the 317 site on chromosome 2, the 303 site on chromosome 2, the 331 site on chromosome 3, the 283 site on chromosome 4, the 231 site on chromosome 4, the 315 site on chromosome 5, the 327 site on chromosome 5, the 305 site on chromosome 5, the 307 site on chromosome 16, the 309 site on chromosome 20, the 285 site on chromosome 6, the 233 site on chromosome 6, the 311 site on chromosome 6, the 299 site on chromosome 6, the 301 site on chromosome 7, the 293 site on chromosome 8, the 319 site on chromosome 11, the 333 site on chromosome 12, the 295 site on chromosome 12, the 329 site on chromosome 12, the 297 site on chromosome 17, the 291 site on chromosome 22, the 313 site on chromosome X and the 321 site on chromosome X.
In a particular embodiment of the invention, the promoter to which the region coding for a fusion protein is functionally linked, comprising a mutant human cytochrome P450 2B6 (CYP2B6*) protein of SEQ ID No. 1 or a variant or fragment thereof, an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof, is a constitutive promoter. Advantageously, the constitutive promoter can be selected from the CMV promoter, the CBA promoter and the EF1-α promoter. Advantageously, the constitutive promoter is the EF1-α promoter.
In a particular embodiment of the invention, the exogenous nucleic acid also comprises a selectable marker gene. By “selectable marker gene” is meant within the meaning of the present invention, a sequence coding for a selectable marker protein, which allows the selective retention of the human stem cells having integrated the exogenous nucleic acid during the culture and propagation of the cells. Advantageously, the selectable marker gene is the CD34 gene; advantageously the CD34 gene having undergone splicing, also called spliced CD34 gene.
Advantageously, the selectable marker gene is the spliced CD34 gene of sequence SEQ ID No. 5:
The use of the spliced CD34 gene makes it possible to select the human stem cells having integrated the exogenous nucleic acid without having signal transduction activity. In a particularly advantageous embodiment, the spliced CD34 selectable marker gene is functionally linked to a nucleic acid of sequence SEQ ID No. 6 coding for the 2A peptide.
The spliced CD34 selectable marker gene is functionally linked to a nucleic acid coding for the 2A peptide and is represented by the nucleic acid sequence SEQ ID No. 7.
Another subject of the invention relates to an expression vector, for example a viral vector, comprising the exogenous nucleic acid as defined above.
Within the meaning of the present invention, the term “vector” denotes a polynucleotide sequence containing the exogenous nucleic acid as defined above and functionally linked control sequences, so that the transformed human stem cells with these sequences are capable of producing encoded proteins, in particular the fusion protein comprising a mutant human cytochrome P450 2B6 (CYP2B6*) protein of SEQ ID No.1 or a variant or fragment thereof and an NADPH-cytochrome P450 reductase protein of SEQ ID No.2 or a variant or fragment thereof.
In a particular embodiment, the human stem cell was obtained by retroviral transduction with a viral vector comprising the exogenous nucleic acid.
The vector generally contains a promoter, initiation and termination signals of the translation, as well as suitable transcription regulation regions. In a particularly advantageous embodiment of the invention, the vector comprises a nucleic acid of sequence SEQ ID No.8 comprising:
In a particular embodiment of the invention, the vector used is a lentiviral vector, advantageously the lentiviral vector pLenti-III-EF1α, marketed by the company Applied Biological Materials Inc.
The vector is held stable in the human stem cell and can optionally possess particular signals that specify the secretion of the translated protein. These different elements are selected and optimized by a person skilled in the art as a function of the host cell used. Such vectors are prepared by methods habitually used by a person skilled in the art, and the resulting clones can be introduced into the appropriate human stem cell by standard methods, such as lipofection, electroporation, the use of polycationic agents, thermal shock, or chemical methods.
In another particular embodiment of the invention, the exogenous nucleic acid can be introduced by different methods into one of the one of the genomic safe harbors, particularly by using effector nucleation techniques of the transcription activator-like effector nuclease (TALEN) type, grouped together as clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) or zinc finger nuclease (ZFN) techniques. Advantageously, the integration of the exogenous nucleic acid in one of the genomic safe harbors is obtained by using clustered regularly interspaced short palindromic repeats (CRISPR/Cas9). Use of this technology in genome editing is well described in the art. In summary, CRISPR is a microbial nuclease system involved in defence against invasive phages and plasmids. The CRISPR loci in microbial hosts contain a combination of genes (Cas) associated with CRISPR as well as non-coding RNA elements capable of programming the cleavage specificity of the nucleic acids (sgRNA) induced by CRISPR. Three types (I-III) of CRISPR systems have been identified over a wide range of bacterial hosts. A key characteristic of each CRISPR locus is the presence of a table of repetitive sequences (direct repetitions) interspersed with short sequences of non-repetitive sequences (spacers). The noncoding CRISPR array is transcribed and cleaved within short direct rcRNA repetitions containing individual spacer sequences, which direct the Cas nucleases to the target site (protospacer). The type II CRISPR is one of the systems that are the best characterized, and produces a targeted double strand DNA break in four sequential steps. Firstly, two noncoding RNAs, the pre-rRNA array and the tracrRNA, are transcribed from the CRISPR locus. Secondly, the tracrRNA hybridizes to the repeat regions of the pre-tRNA and intervenes in processing pre-rRNA into mature rRNA containing individual spacer sequences. Thirdly, the mature tRNA: tracrRNA complex directs Cas9 to the target DNA via matching of the Watson-Crick bases between the spacer situated on the rRNA and the protospacer situated on the target DNA, beside the protospacer adjacent motif (PAM), a supplementary requirement for recognition of the target. Finally, Cas9 intervenes in the cleavage of the target DNA in order to create a double-strand break in the protospacer. Cas9 is therefore the characteristic protein of the CRISPR-Cas type II system and a big monomer DNA nuclease guided towards a target DNA sequence adjacent to the PAM (protospacer adjacent motif) sequence by a complex of two noncoding RNAs: CRISPR RNA (rRNA) and trans-activating rRNA (tracrRNA). The Cas9 protein contains two nuclease domains homologous to the RuvC and HNH nucleases. The HNH nuclease domain cleaves the complementary DNA strand while the RuvC domain cleaves the non-complementary strand and, consequently, a complete cut is introduced in the target DNA. The heterologous expression of Cas9 with an sgRNA can introduce specific double-strand breaks (DSB) at the site in the genomic DNA of living cells of various organisms. For applications in eucaryotic organisms, Cas9 codon-optimized versions, originating from the bacterium Streptococcus pyogenes, were used. Single guide RNA (sgRNA) is the second component of the CRISPR/Cas system that forms a complex with the Cas9 nuclease. The sgRNA is a synthetic RNA chimera created by the fusion of cRNA and tracrRNA. The gRNA guide sequence situated at the 5′ end confers the specificity on the target DNA. Consequently, by modifying the guide sequence, it is possible to create sgRNAs with different target specificities. The canonical length of the guide sequence is 20 bp. The Cas9 expression vectors intended to be used in the methods of the invention can be constructed as described in the art.
Another subject of the invention relates to the genetically modified human stem cell as defined above for use thereof as a medicament. In particular, the present invention relates to the genetically modified human stem cell as defined above for use thereof in the prevention and/or the treatment of cancer and/or cancer recurrences and/or associated metastases.
Advantageously, the cancer is a cancer selected from: cancers affecting the central nervous system, such as astrocytomas and gliomas; cancers of the upper aerodigestive tract (ENT), such as cancer of the lips, cancer of the oral cavity, oropharyngeal and nasopharyngeal cancer; cancers of the endocrine glands, such as thyroid cancer, cancer of the adrenal glands and extra-digestive and pulmonary neuroendocrine tumours; cancers of the exocrine glands, such as breast cancer and pancreatic cancer; cancers affecting the thorax, such as pleural and lung cancer; digestive system cancers, such as cancer of the oesophagus, stomach cancer, small bowel cancer, colon cancer and rectal and/or anal cancer; genital cancers, such as prostate cancer, cervical cancer, endometrial cancer, cancer of the vagina and cancer of the vulva; urinary system cancers, such as kidney cancer and bladder cancer; sarcomas, such as soft tissue sarcoma, gastro-intestinal stromal tumours (GIST) and bone sarcoma; skin cancers, such as melanoma; hepatobiliary cancers, such as hepatocellular carcinoma and cholangiocarcinoma, the list being non-limitative.
Advantageously, the invention relates to the genetically modified human stem cell as defined above for use thereof in the prevention and/or the treatment of the solid tumours, in particular hepatocellular carcinomas, and/or cancer recurrences and/or associated metastases.
According to a particularly advantageous embodiment of the invention, the genetically modified human stem cell according to the invention is particularly useful for preventing and/or treating cancer and/or cancer recurrences and/or associated metastases.
According to a particularly advantageous embodiment of the invention, the genetically modified human stem cell according to the invention is particularly useful for preventing and/or treating the solid tumours and/or cancer recurrences and/or associated metastases.
According to a particularly advantageous embodiment of the invention, the genetically modified human stem cell according to the invention is particularly useful for preventing and/or treating a cancer and/or cancer recurrences and/or associated metastases selected from: cancers affecting the central nervous system, such as astrocytomas and gliomas; cancers of the upper aerodigestive tract (ENT), such as cancer of the lips, cancer of the oral cavity, oropharyngeal and nasopharyngeal cancer; cancers of the endocrine glands, such as thyroid cancer, cancer of the adrenal glands and extra-digestive and pulmonary neuroendocrine tumours; cancers of the exocrine glands, such as breast cancer and pancreatic cancer; cancers affecting the thorax, such as pleural and lung cancer; digestive system cancers, such as cancer of the oesophagus, stomach cancer, small bowel cancer, colon cancer and rectal and/or anal cancer; genital cancers, such as prostate cancer, cervical cancer, endometrial cancer, cancer of the vagina and cancer of the vulva; urinary system cancers, such as kidney cancer and bladder cancer; sarcomas, such as soft tissue sarcoma, gastro-intestinal stromal tumours (GIST) and bone sarcoma; skin cancers, such as melanoma; hepatobiliary cancers, such as hepatocellular carcinoma and cholangiocarcinoma, the list being non-limitative.
According to a particularly advantageous embodiment of the invention, the genetically modified human stem cell according to the invention is particularly useful for preventing and/or treating hepatocellular carcinomas and/or associated metastases.
Another aspect of the invention relates to a method for selecting genetically modified stem cells as defined above, characterized in that it comprises the steps of:
a) transducing the human stem cells with a viral vector comprising the exogenous nucleic acid,
b) culturing the human stem cells originating from step a) in a predefined culture medium, and
c) selecting the genetically modified human stem cells expressing the selectable marker gene on their membrane surface.
In a particular embodiment of the invention, the culture medium used is a specific medium for human stem cells, such as the Mesenchymal Stem Cell Growth Medium 2, marketed by Promocell (Product reference: C28009).
Advantageously, the culture medium used comprises 50% of medium having been in contact with the non-transduced human stem cells for 24 hours and 50% fresh of the same medium.
In a particular embodiment, the selectable marker gene is the spliced CD34 gene. Advantageously, the selection of the genetically modified human stem cells expressing the selectable marker gene on their membrane surface is carried out by flow cytometry, in particular by means of the BD-FACS ARIAIII™ appliance, using fluorochrome-coupled anti-CD34 antibodies “Brilliant Violet421™” anti-human CD34 Antibody (Product reference: 343609 from Biolegend).
Another subject of the invention relates to a pharmaceutical composition comprising the genetically modified human stem cell according to the invention as active ingredient and at least one pharmaceutically acceptable excipient. In a particular embodiment of the invention, the pharmaceutical composition according to the invention comprises a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient.
According to a particularly advantageous embodiment of the invention, the pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above is particularly useful for preventing and/or treating cancer and/or cancer recurrences and/or associated metastases.
Advantageously, the pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above is administered to a patient suffering from, or suspected of suffering from, cancer and/or cancer recurrences and/or associated metastases.
Advantageously, the cancer is a cancer with solid tumours. By “solid tumour” within the meaning of the present invention, is meant a carcinoma or a sarcoma. In a particular embodiment of the invention, the cancer is a cancer selected from: cancers affecting the central nervous system, such as astrocytomas and gliomas; cancers of the upper aerodigestive tract (ENT), such as cancer of the lips, cancer of the oral cavity, oropharyngeal and nasopharyngeal cancer; cancers of the endocrine glands, such as thyroid cancer, cancer of the adrenal glands and extra-digestive and pulmonary neuroendocrine tumours; cancers of the exocrine glands, such as breast cancer and pancreatic cancer; cancers affecting the thorax, such as pleural and lung cancer; digestive system cancers, such as cancer of the oesophagus, stomach cancer, small bowel cancer, colon cancer and rectal and/or anal cancer; genital cancers, such as prostate cancer, cervical cancer, endometrial cancer, cancer of the vagina and cancer of the vulva; urinary system cancers, such as kidney cancer and bladder cancer; sarcomas, such as soft tissue sarcoma, gastro-intestinal stromal tumours (GIST) and bone sarcoma; skin cancers, such as melanoma; hepatobiliary cancers, such as hepatocellular carcinoma and cholangiocarcinoma, the list being non-limitative.
According to a particularly advantageous embodiment of the invention, the pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above is particularly useful for preventing and/or treating the solid tumours, and in particular hepatocellular carcinomas, and/or cancer recurrences and/or associated metastases.
Advantageously, the pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above is administered to a patient suffering from, or suspected of suffering from, solid tumours, and in particular hepatocellular carcinomas, and/or cancer recurrences and/or associated metastases.
In an embodiment, the patient can be a human being, man or woman, regardless of age. In another embodiment, the patient can be a non-human animal, advantageously a non-human mammal, for example a dog, a cat, a mouse, a rat, a hamster, a rabbit, a chinchilla, a horse, a cow, a pig, a sheep, a goat or a primate.
Within the meaning of the present invention, the terms “therapeutically efficacious” or “efficacious quantity for treatment”, or “pharmaceutically efficacious” denote the quantity of genetically modified human stem cells necessary to inhibit or reverse a disease, advantageously a cancer, and in particular for treating the solid tumours and particularly hepatocellular carcinomas, and/or associated metastases. The determination of a therapeutically efficacious quantity depends specifically on factors such as the toxicity and efficacy of the medicament. These factors will differ as a function of other factors such as the activity, the relative bioavailability, the body weight of the patient, the severity of the adverse effects and the preferred administration route. The toxicity can be determined by using methods that are well known in the art. The same applies for the efficacy. A pharmaceutically efficacious quantity is consequently a quantity that is considered by the clinician as toxicologically tolerable but efficacious.
The dosage can be adjusted appropriately to achieve the desired medicament levels (for example, of genetically modified human stem cells), local or systemic, in particular transarterial, as a function of the administration route. In the case where a patient's response is insufficient at such doses, higher doses (or more efficacious doses via a different, more localized administration route) can be used to the extent that the patient's tolerance permits. Several injections at approximately one week's interval can also be used to achieve appropriate levels of toxic metabolites formed to elicit the death of the tumour cells and the triggering of an antitumor immune response. “Dose” and “dosage” are used interchangeably herein.
The frequency of injection is linked to the half-life of the genetically modified human stem cells.
In an advantageous embodiment, the pharmaceutical composition according to the invention is administered to the patient at the rate of one administration per week for at least four weeks. Advantageously, the pharmaceutical composition according to the invention is administered to the patient at the rate of two administrations, advantageously three administrations, advantageously four administrations, advantageously five administrations, advantageously six administrations, advantageously seven administrations per week. Advantageously, the pharmaceutical composition according to the invention is administered to the patient for at least four weeks, advantageously at least five weeks, advantageously at least six weeks, advantageously at least seven weeks, advantageously at least eight weeks, advantageously at least nine weeks, advantageously at least ten weeks.
In an advantageous embodiment, the pharmaceutical composition according to the invention also comprises at least a second active ingredient. In a particularly advantageous embodiment of the invention, the at least a second active ingredient can interact synergically with the genetically modified human stem cells according to the invention.
Advantageously, the second active ingredient is an anti-cancer agent. By way of example of second active ingredient, there may be mentioned particularly the cytostatic agents, the cytotoxic agents, the cytoprotective agents, the growth inhibitor agents, the toxins and combinations thereof. Examples of anti-cancer agents capable of being used in tumour therapy with the genetically modified human stem cells of the invention comprise cyclophosphamide (CAS No. 50-18-0, also known as cyclophosphane, and the trade names Endoxan®, Neosar®, Procytox® and Revimmune®), AQ4N (1, 4) -bis- {[2- (dimethylamino-N-oxide) ethyl] amino} 5,8-dihydroxyanthracene-9,10-dione, (also known as Banoxantrone®), Ifosfamide (CAS No. 3778-73-2), Bezyloxyresorufine, 7-Ethoxy-4-trifluoro-methyl-coumarin (EFC), Bupropion, Thiotepa (N,N′N′-triethylenethiophosphoramide, CAS No. 52-24-4), mytomycin C (CAS No. 50-O-07), tirapazamine (SR-4233, CAS No. 27314-97-2). By way of examples of cytoprotective agent, mesna may be mentioned particularly, also known under the trade name of Uromitexan®. Advantageously, the second active ingredient can comprise a combination of anti-cancer agents, such as those listed above. In a particularly advantageous embodiment, the second active ingredient is a combination of an anti-cancer and a cytoprotective agent. In a particularly advantageous embodiment, the second active ingredient is a combination of cyclophosphamide and mesna.
In a particular embodiment, the pharmaceutical composition according to the invention comprises the genetically modified human stem cells as defined above as active ingredient and cyclophosphamide as second active ingredient.
In a particular embodiment, the pharmaceutical composition according to the invention comprises the genetically modified human stem cells as defined above as active ingredient and mesna as second active ingredient.
In a particular embodiment according to the invention, the second active ingredient can be in the form of granules, powders, tablets, coated tablets, (micro)capsules, syrups, emulsions, suspensions or prolonged-release preparations. In another particular embodiment according to the invention, the second active ingredient can be in a form that can be administered via parenteral route.
In a particular embodiment, the pharmaceutical composition according to the invention comprises the genetically modified human stem cells as defined above as active ingredient and cyclophosphamide as second active ingredient and at least one pharmaceutically acceptable excipient.
In a particular embodiment, the pharmaceutical composition according to the invention comprises genetically modified human stem cells as defined above as active ingredient and cyclophosphamide as second active ingredient and at least one pharmaceutically acceptable excipient.
In an advantageous embodiment of the invention, when the pharmaceutical composition comprises a second active ingredient, the pharmaceutical composition is adapted for a simultaneous administration or a sequential administration of the genetically modified human stem cells and of the second active ingredient.
Within the meaning of the present invention, by “simultaneous administration” is meant an administration of the genetically modified human stem cells and of the second active ingredient at the same time, at the same moment, to a patient in therapeutically efficacious quantities in order to permit the synergic effect of the pharmaceutical composition. This does not necessarily mean that the genetically modified human stem cells and the second active ingredient must be administered in the form of a mixture; they can in fact be administered simultaneously but separately, in the form of distinct compositions.
By “present in two distinct compositions” is meant that the genetically modified human stem cells and the second active ingredient are physically separate. They are then implemented, administered separately in therapeutically efficacious quantities, to permit the synergic effect of the pharmaceutical composition, without prior mixing, in several (at least two) dosage forms (for example two distinct compositions).
In another particular embodiment of the invention, the genetically modified human stem cells and the second active ingredient can be present in one and the same composition in therapeutically efficacious quantities in order to permit the synergic effect of the pharmaceutical composition. Within the meaning of the present invention, by “present in one and the same composition” is meant the physical combination of the genetically modified human stem cells and the second active ingredient. The genetically modified human stem cells and the second active ingredient must then be administered simultaneously, as they are administered together in the form of a mixture, in one and the same dosage form (for example in a single composition containing the genetically modified human stem cells and the anti-cancer agent) and in therapeutically efficacious quantities, to permit the synergic effect of the pharmaceutical composition.
Within the meaning of the present invention, by the expression “sequential administration” is meant that the genetically modified human stem cells and the second active ingredient are administered in therapeutically efficacious quantities in order to permit the synergic effect of the pharmaceutical composition, not simultaneously but separately over time, one after another. The terms “precede” or “preceding” and “follow” or “following” then apply. The term “precede” or “preceding” is used when a component of the pharmaceutical composition according to the invention is administered a few minutes or a few hours, or even a few days before the administration of the other component(s) of the pharmaceutical composition. Conversely, the term “follow” or “following” is used when a component of the pharmaceutical composition according to the invention is administered a few minutes or a few hours, or even a few days after the administration of the other component(s) of the pharmaceutical composition. In a particularly advantageous embodiment of the invention, the genetically modified human stem cells are administered several days before the second active ingredient.
In an advantageous embodiment of the invention, when the pharmaceutical composition comprises a second active ingredient, the pharmaceutical composition is adapted for a sequential administration of the genetically modified human stem cells and of the second active ingredient. Advantageously, the second active ingredient is cyclophosphamide used alone or in combination with mesna.
In a particular embodiment of the invention, the genetically modified human stem cells are administered to the patient, then two or three days after the administration of the genetically modified human stem cells, cyclophosphamide, alone or in combination with mesna, is administered to this same patient, at the rate of two administrations of genetically modified human stem cells and of cyclophosphamide, alone or in combination with mesna, per week for at least four weeks, advantageously at least five weeks, advantageously at least six weeks, advantageously at least seven weeks, advantageously at least eight weeks, advantageously at least nine weeks, advantageously at least ten weeks.
As a function of the intended in vivo administration route, the pharmaceutical composition used can be in the solid, semi-solid or liquid dosage form, such as for example tablets, pills, powders, capsules, gels, ointments, liquids, suspensions or similar. Preferably, the pharmaceutical compositions are administered in suitable unitary dosage forms for single administration in precise dosage quantities. The pharmaceutical compositions can also comprise, as a function of the desired formulation, at least one pharmaceutically acceptable support or diluent, which are defined as aqueous-base vehicles currently used for formulations intended for human administration. The diluent is selected so as not to affect the biological activity of the active constituents present in the pharmaceutical composition of the invention. Examples of such diluents are distilled water, physiological serum, Ringer solution, dextrose solution and Hank's solution. Efficacious quantities of such a diluent or support are efficacious quantities for obtaining a pharmaceutically acceptable formulation in terms of solubility of the constituents, biological activity, etc. In certain embodiments, the pharmaceutical constituents herein are sterile.
Suitable pharmaceutical preparation liquid forms can particularly comprise aqueous or saline solutions, said aqueous or saline solutions being able to be micro-encapsulated, notched, applied onto microscopic gold particles, contained in liposomes.
The administration of the pharmaceutical composition or of the genetically modified human stem cell according to the present invention can be carried out via any administration route, including via oral, topical, parenteral (also called systemic or general route), intramuscular, intranasal, sublingual, intratracheal routes, via inhalation, ocular, vaginal and rectal routes. Intracapsular, intravenous, transarterial, intraarterial and intraperitoneal administration routes can also be used. A person skilled in the art will know how to select the appropriate administration route as a function of the disorder to be treated.
Advantageously, the pharmaceutical composition or the genetically modified human stem cell according to the present invention can be administered to a subject via parenteral route, advantageously via transarterial route.
When it is desirable to administer them via systemic route, the compositions can be formulated for parenteral administration by injection, for example by bolus injection or continuous perfusion. The formulations for injection can be presented in a unitary dosage form, for example in ampoules or multiple-dose containers, with an added preservative. The compositions can adopt forms such as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulation agents such as suspension agents, stabilizers and/or dispersants.
The pharmaceutical formulations for parenteral administration comprise aqueous solutions of the active compositions in water-soluble form. In addition, suspensions of the active compositions can be prepared in the form of appropriate suspensions for oily injection. The appropriate lipophilic solvents or vehicles comprise fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. The aqueous suspensions for injection can contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol or dextran. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compositions, to permit the preparation of highly concentrated solutions. As a variant, the active compositions can be in the form of powders to be made up with a suitable vehicle, for example pyrogen-free sterile water, before use.
Even more advantageously, the pharmaceutical composition or the genetically modified human stem cell according to the present invention can be administered to a patient via transarterial route. According to a particular embodiment of the invention, the pharmaceutical composition or the genetically modified human stem cell according to the present invention are in a suitable form for administration thereof via transarterial route.
In a particularly advantageous embodiment, the genetically modified human stem cells according to the present invention represent a ratio of 0.5 á 98% by weight, or more, of the total weight of the pharmaceutical composition in question.
In a particularly advantageous embodiment of the present invention, the pharmaceutical composition according to the invention comprises only the genetically modified human stem cells as defined above, as single active ingredient.
Another subject of the invention relates to a method for the preventive treatment of cancer and/or associated metastases, comprising administration to the patient of genetically modified human stem cells or of a pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above.
Within the meaning of the present invention, the term “prevention” or “prophylaxis” or “preventative treatment” or “prophylactic treatment” comprises a treatment leading to the prevention of a disease as well as a treatment reducing and/or delaying the incidence of a disease or the risk of occurrence of the disease.
According to the present invention, the genetically modified human stem cell is particularly efficacious for preventing recurrences and the appearance of new metastases, by eliciting a strong antitumor immune response, thus inducing a protective effect against recurrences and metastases.
In a particularly advantageous embodiment, the present invention relates to a method for the preventive treatment of cancer and/or cancer recurrences and/or associated metastases, comprising administration to the patient of genetically modified human stem cells or of a pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above and a second active ingredient as defined above.
Advantageously, the cancer is a cancer with solid tumours. By “solid tumour” within the meaning of the present invention, is meant a carcinoma or a sarcoma. In a particular embodiment of the invention, the cancer is a cancer selected from: cancers affecting the central nervous system, such as astrocytomas and gliomas; cancers of the upper aerodigestive tract (ENT), such as cancer of the lips, cancer of the oral cavity, oropharyngeal and nasopharyngeal cancer; cancers of the endocrine glands, such as thyroid cancer, cancer of the adrenal glands and extra-digestive and pulmonary neuroendocrine tumours; cancers of the exocrine glands, such as breast cancer and pancreatic cancer; cancers affecting the thorax, such as pleural and lung cancer; digestive system cancers, such as cancer of the oesophagus, stomach cancer, small bowel cancer, colon cancer and rectal and/or anal cancer; genital cancers, such as prostate cancer, cervical cancer, endometrial cancer, cancer of the vagina and cancer of the vulva; urinary system cancers, such as kidney cancer and bladder cancer; sarcomas, such as soft tissue sarcoma, gastro-intestinal stromal tumours (GIST) and bone sarcoma; skin cancers, such as melanoma; hepatobiliary cancers, such as hepatocellular carcinoma and cholangiocarcinoma, the list being non-limitative. Advantageously, the cancer is a solid tumour, in particular a hepatocellular carcinoma, and/or cancer recurrences and/or associated metastases.
In a particularly advantageous embodiment, the present invention relates to a method for the preventive treatment of hepatocellular carcinoma, comprising administration to the patient of genetically modified human stem cells or of a pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above.
In a particularly advantageous embodiment, the present invention relates to a method for the preventive treatment of hepatocellular carcinoma, comprising administration to the patient of genetically modified human stem cells or of a pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above and a second active ingredient as defined above.
In a particularly advantageous embodiment, the present invention relates to the use of a pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient in the production of a medicament intended for the prevention of cancer and/or cancer recurrences and/or associated metastases.
Advantageously, the cancer is a cancer with solid tumours. By “solid tumour” within the meaning of the present invention, is meant a carcinoma or a sarcoma. In a particular embodiment of the invention, the cancer is a cancer selected from: cancers affecting the central nervous system, such as astrocytomas and gliomas; cancers of the upper aerodigestive tract (ENT), such as cancer of the lips, cancer of the oral cavity, oropharyngeal and nasopharyngeal cancer; cancers of the endocrine glands, such as thyroid cancer, cancer of the adrenal glands and extra-digestive and pulmonary neuroendocrine tumours; cancers of the exocrine glands, such as breast cancer and pancreatic cancer; cancers affecting the thorax, such as pleural and lung cancer; digestive system cancers, such as cancer of the oesophagus, stomach cancer, small bowel cancer, colon cancer and rectal and/or anal cancer; genital cancers, such as prostate cancer, cervical cancer, endometrial cancer, cancer of the vagina and cancer of the vulva; urinary system cancers, such as kidney cancer and bladder cancer; sarcomas, such as soft tissue sarcoma, gastro-intestinal stromal tumours (GIST) and bone sarcoma; skin cancers, such as melanoma; hepatobiliary cancers, such as hepatocellular carcinoma and cholangiocarcinoma, the list being non-limitative. Advantageously, the cancer is a solid tumour, in particular a hepatocellular carcinoma and/or associated metastases.
In a particularly advantageous embodiment, the present invention relates to the use of a pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient in the production of a medicament intended for the prevention of solid tumours, and in particular hepatocellular carcinomas, and/or cancer recurrences and/or associated metastases.
Another subject of the invention relates to a method for the curative treatment of cancer and/or associated metastases in patients requiring an administration, comprising administration to said patients of genetically modified human stem cells or of a pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above.
Within the meaning of the present invention, the term “treatment” or “curative treatment” is defined as a treatment leading to recovery or treatment that relieves, ameliorates and/or eliminates, reduces and/or stabilizes the symptoms of a disease or the suffering that it elicits.
Another subject of the invention relates to a method for the curative treatment of cancer and/or cancer recurrences and/or associated metastases in patients requiring an administration, comprising administration to said patients of genetically modified human stem cells or of a pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above and a second active ingredient as defined above.
Advantageously, the cancer is a cancer with solid tumours. By “solid tumour” within the meaning of the present invention, is meant a carcinoma or a sarcoma. In a particular embodiment of the invention, the cancer is a cancer selected from: cancers affecting the central nervous system, such as astrocytomas and gliomas; cancers of the upper aerodigestive tract (ENT), such as cancer of the lips, cancer of the oral cavity, oropharyngeal and nasopharyngeal cancer; cancers of the endocrine glands, such as thyroid cancer, cancer of the adrenal glands and extra-digestive and pulmonary neuroendocrine tumours; cancers of the exocrine glands, such as breast cancer and pancreatic cancer; cancers affecting the thorax, such as pleural and lung cancer; digestive system cancers, such as cancer of the oesophagus, stomach cancer, small bowel cancer, colon cancer and rectal and/or anal cancer; genital cancers, such as prostate cancer, cervical cancer, endometrial cancer, cancer of the vagina and cancer of the vulva; urinary system cancers, such as kidney cancer and bladder cancer; sarcomas, such as soft tissue sarcoma, gastro-intestinal stromal tumours (GIST) and bone sarcoma; skin cancers, such as melanoma; hepatobiliary cancers, such as hepatocellular carcinoma and cholangiocarcinoma, the list being non-limitative. Advantageously, the cancer is a solid tumour, in particular a hepatocellular carcinoma and/or associated metastases.
Another subject of the invention relates to a method for the curative treatment of a solid tumour, advantageously of the hepatocellular carcinomas and/or associated metastases, in patients requiring an administration, comprising administration to said patients of genetically modified human stem cells or of a pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above.
Another subject of the invention relates to a method for the curative treatment of a solid tumour, advantageously of the hepatocellular carcinomas and/or associated metastases, in patients requiring an administration, comprising administration to said patients of genetically modified human stem cells or of a pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above and a second active ingredient as defined above. In a particularly advantageous embodiment, the present invention relates to the use of a pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient in the production of a medicament intended for the treatment of cancer and/or of associated metastases.
Advantageously, the cancer is a cancer with solid tumours. By “solid tumour” within the meaning of the present invention, is meant a carcinoma or a sarcoma. In a particular embodiment of the invention, the cancer is a cancer selected from: cancers affecting the central nervous system, such as astrocytomas and gliomas; cancers of the upper aerodigestive tract (ENT), such as cancer of the lips, cancer of the oral cavity, oropharyngeal and nasopharyngeal cancer; cancers of the endocrine glands, such as thyroid cancer, cancer of the adrenal glands and extra-digestive and pulmonary neuroendocrine tumours; cancers of the exocrine glands, such as breast cancer and pancreatic cancer; cancers affecting the thorax, such as pleural and lung cancer; digestive system cancers, such as cancer of the oesophagus, stomach cancer, small bowel cancer, colon cancer and rectal and/or anal cancer; genital cancers, such as prostate cancer, cervical cancer, endometrial cancer, cancer of the vagina and cancer of the vulva; urinary system cancers, such as kidney cancer and bladder cancer; sarcomas, such as soft tissue sarcoma, gastro-intestinal stromal tumours (GIST) and bone sarcoma; skin cancers, such as melanoma; hepatobiliary cancers, such as hepatocellular carcinoma and cholangiocarcinoma, the list being non-limitative.
In a particularly advantageous embodiment, the present invention relates to the use of a pharmaceutical composition comprising a therapeutically efficacious quantity of genetically modified human stem cells as active ingredient in the production of a medicament intended for the treatment of the solid tumours, and in particular hepatocellular carcinomas, and/or associated metastases.
| Number | Date | Country | Kind |
|---|---|---|---|
| FR1911386 | Oct 2019 | FR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2020/078806 | 10/13/2020 | WO |
